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http://dx.doi.org/10.1016/j.kjms.201Abstract Eradication of Helicobacter pylori infection has become an important issue
recently, because this bacterial species cluster can cause many gastrointestinal diseases.
Elevated antibiotic resistance is related to an increasing failure rate of H. pylori eradication.
Standard triple therapy is still the first-line therapy; however, according to the Maastricht IV
Consensus Report, it should be abandoned in areas of high clarithromycin resistance. Alterna-
tive first-line therapies include bismuth-containing quadruple therapy, sequential, concomi-
tant, and hybrid therapies. Quinolone-based triple therapy may be considered as first-line
therapy in areas of clarithromycin resistance >15e20% and quinolone resistance <10%. Unique
second-line therapy is still unclear, and bismuth-containing quadruple therapy or levofloxacin-
based triple therapy can be used as rescue treatment. Third-line therapy should be under
culture guidance to select the most effective regimens (such as levofloxacin-based, rifabu-
tin-based, or furazolidone-based therapies). Antibiotics resistance, patient compliance, and
CYP 2C19 genotypes could influence the outcome. Clinicians should use antibiotics according
to local reports.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.clare no conflicts of interest.
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Helicobacter pylori, a Gram-negative bacterium found in
the stomach, has been shown to be the pathogen con-
nected to many gastrointestinal diseases, such as peptic
ulcer disease and gastric mucosa-associated lymphoid tis-
sue lymphoma [1]. Thus, successful eradication of H. pyloried by Elsevier Taiwan LLC. All rights reserved.
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recommendations from the Maastricht IV Consensus Report,
the first-line regimen for H. pylori eradication includes
proton pump inhibitor (PPI), clarithromycin (CAM), and
amoxicillin (AMX) or metronidazole (MET) [2]. However, it
also recommends that this regimen should be abandoned
when the CAM-resistance rate in the region is >15e20%,
because many studies published recently have demon-
strated that the intention to treatment (ITT) eradication
rate is falling short of 80% [3e5], which is defined as the
acceptable level in the Maastricht guidelines [2]. Among
the factors [antibiotic resistance, poor compliance, high
gastric acidity, high bacterial load, and cytochrome P450
2C19 (CYP2C19) polymorphism] that contribute to the
decline of H. pylori eradication rate [6], antibiotic resis-
tance is thought to play a cardinal role [7e9]. Alternative
strategies have been developed aiming to overcome
treatment failure. This article reviews recent novel and
acceptable regimens and the factors influencing the effi-
cacy of eradication.The challenge of H. pylori eradication
Generally speaking, the optimized therapy for microbial
infection depends on the appropriate selection of antimi-
crobial regimens to which the infected microbes are sus-
ceptible. However, the susceptibility of H. pylori to the
antibiotics that are commonly used is changing. Within the
antibiotics in the H. pylori eradication regimens, CAM and
MET resistance is the most important, because this cannot
be overcome by increasing dosage or duration [10]. The
prevalence of the resistant strains is variable in different
geographic areas. For example, in the study from De
Francesco et al. [11], the prevalence of CAM-resistant
strains in America was 29.3%, which was higher than that
in Asia (18.9%) and Europe (11.1%). Furthermore, the exis-
tence of the CAM-resistance strain was low in The
Netherlands (1%) compared with other European countries.
Therefore, it is suggested that the antibiotic selection for
the eradication regimen should be based on local resistance
reports [10].
Another issue that influences the efficacy of H. pylori
eradication is the intragastric acidity. The low pH level of
the gastric environment might affect the stabilization of
acid-labile antibiotics, such as CAM [12]. The PPI in the
eradication regimen is responsible for the elevation of
intragastric pH level, and its effect depends on the
different genotypes of CYP2C19, which results in different
degrees of PPI metabolism individually. The distribution of
the three genotypes, extensive metabolizer (EM), inter-
mediate metabolizer (IM), and poor metabolizer (PM), is
variable in different regions. The proportion of individuals
with PM genotype is higher in Asia (20%) than in Western
countries (5%) [13,14]. The PM genotype is connected with
higher intragastric pH level, better transportation of anti-
biotics from plasma to gastric juice with increasing luminal
concentrations, and higher effectiveness in eradication of
H. pylori [12]. Within all the PPIs, rabeprazole and eso-
meprazole appear relatively less influenced by CYP2C19
[12,14]. One study has mentioned that increasing the
dosage of omeprazole (from 20 mg to 40 mg) might improvethe efficacy of eradication [15]; however, this observation
is still questionable [16,17].
It is still uncertain as to whether genotyping of CYP2C19
should be performed prior to starting second-line H. pylori
therapy. According to the Second AsiaePacific consensus, it
is not necessary because of the cost and low availability
[18].
First-line therapy
Standard triple therapy
Recently, it was suggested that the standard triple therapy
should now be avoided owing to increasing resistance
[2,10]. The reason is the increasing CAM- or MET-resistant
strains of H. pylori [10]. A study from Japan reporting the
change in the standard triple therapy eradication rate in
the 12-year observation period between 1997 and 2008
disclosed that the prevalence of CAM-resistant strains
increased from 8.7% to 34.5%, in opposition to the trend in
the eradication rate from 90.6% to 74.8% [5]. A meta-
analysis showed that the CAM- or MET-resistant strains
increased globally, and was considered to be responsible
for the decline in the eradication rate [9]. When the
prevalence of resistant strain reaches >15e20%, the erad-
ication rate often decreases to <85% in per-protocol (PP)
analysis and 80% in ITT analysis respectively [9,19,20]. This
observation raises a question whether the regimen is still
suitable for the choice of first-line therapy. When
comparing the eradication rates between CAM-sensitive
and CAM-resistant strains, the standard triple therapy has
a drastically different performance between the two
groups (88% vs. 18%) [9]. This finding gives the traditional
regimen promise in areas where the CAM or MET resistance
is relatively low (1% in The Netherlands) [11]. Therefore,
whether the triple therapy remains the standard first-line
regimen depends on the local prevalence of the
antibiotic-resistant strain of H. pylori.
Several issues have been mentioned for the improve-
ment of the eradication rate [2]. One of them is the
extended duration of the standard triple therapy. One
study reporting from seven Latin American sites revealed
that 14-day triple therapy still could reach an 82.2% erad-
ication rate (ITT) [21], demonstrating that prolonged
duration may be an alternative method in improving the
performance of standard triple therapy regimen, especially
for regions where bismuth therapy is not available.
Alternative first-line eradication regimens
Bismuth-containing therapy has been mentioned as a suc-
cessful therapy since the 1990s [22]. The original 14-day
regimen contained bismuth and two antibiotics (MET and
tetracycline). Later, the alternative version with added PPI
(bismuth-containing quadruple therapy) showed its ability
to overcome MET resistance [22]. However, this regimen
has not been widely used because of the administration of a
large number of pills, high cost, poor compliance, severe
side effects, and unavailability of bismuth. Currently, this
quadruple therapy with 10-day duration is advocated as an
alternative first-line regimen for H. pylori eradication
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The study from Malfertheiner et al. [27] further demon-
strated that this regimen improved the eradication rate in
both CAM- and/or MET-resistance groups with ITT analysis
>90% [27]. Therefore, the quadruple therapy could be the
alternative first-line treatment, especially in areas with
high prevalence of CAM or MET resistance.
Interestingly, in the meta-analysis of the prevalence of
antibiotic-resistant strains, the primary resistance of H.
pylori to AMX was low globally [9]. A new regimen con-
sisting of 5 days dual therapy with a PPI [standard dose,
twice daily (b.i.d.)] and AMX (1000 mg, b.i.d.), followed by
5 days triple therapy with a PPI (standard dose, b.i.d.),
clarithromycin (500 mg, b.i.d.), and MET (500 mg, b.i.d.) or
imidazole, has been developed. Clinically, the eradication
rate via this sequential therapy regimen has reached 90%
[28e30], and its performance is better than standard triple
therapy for 7 days or 10 days [odds ratio 1.21; 95% confi-
dence interval (CI): 1.17e1.25] in areas with high preva-
lence of CAM or MET resistance, such as Italy [31].
Furthermore, Vaira et al. [28] reported that sequential
therapy still had a high eradication rate (89% by PP analysis)
when facing the CAM-resistant strain [28].
The efficacy of sequential therapy for H. pylori eradi-
cation in Asia remains unclear, although a study in Taiwan
showed sequential therapy had a higher eradication rate
than standard triple therapy [32]. However, not all the
studies evaluating the sequential therapy performance in
CAM-resistant strains have reached such a high success
rate. A report from Thailand showed a 57.1% eradication
rate in a culture-based CAM-resistance group [29]. This
observation agrees with the conclusion from the meta-
analysis that the efficacy of sequential therapy in areas
with a high prevalence of CAM resistance or dual CAM and
MET resistance is the challenge [31,33]. Another issue for
this regimen is the complexity of the administration that
might reduce the compliance. However, one study stated
that there was no significant different in compliance be-
tween sequential therapy and concomitant therapy [34].
Concomitant therapy consists of a PPI (standard dose,
b.i.d.) and three antibiotics [CAM (500 mg, b.i.d.), AMX
(1 g, b.i.d.), and MET (500 mg, b.i.d.)]; all four drugs given
together with variable duration from 3 days to 7 days. A
meta-analysis including five qualifying randomized
controlled trials comparing concomitant (293 patients,
duration 3e5 days) and triple therapy (283 patients, dura-
tion 5e10 days) showed superiority of concomitant therapy
over standard triple therapy with pooled odds ratio of 2.86
(95% CI: 1.73e4.73; by ITT analysis) [35]. In a study in
comparison with concomitant and sequential therapy, both
regimens had similar eradication rates (93.0% vs. 92.3.0% by
ITT analysis) and drug compliance [34]; however, concom-
itant therapy has shorter duration and less complex drug
administration than sequential therapy.
A novel regimen combining sequential and concomitant
models was developed. This so-called hybrid therapy has
two phases: dual therapy with a PPI (standard dose, b.i.d.)
and AMX (1 g, b.i.d.) for 7 days, followed by a non-bismuth
quadruple therapy consisting of a PPI (standard dose,
b.i.d.), AMX (1 g, b.i.d.), CAM (500 mg, b.i.d.), and MET
(500 mg, b.i.d.) for a further 7 days [36]. The benefit of the
extended duration of AMX administration is to reducefurther the bacterial load for improving the eradication
rate. It has been demonstrated by a study from Taiwan,
that in ITT analysis, the eradication rate reached 97.4%
[36]. This study also mentioned the efficacy of the hybrid
therapy regimen in the treatment of H. pylori with dual
resistance, but further studies are necessary.
Levofloxacin, one of the new generation of quinolone
drugs, has been introduced into the treatment of H. pylori
as a component of second-line or rescue regimens. How-
ever, the increase of CAM-resistant strains and the decline
of the eradication rate have made many clinical trials
choosing levofloxacin in replacement of CAM, an alternative
first-line regimen. A study reviewing its efficacy reported
that the eradication rate of levofloxacin-based triple
therapy ranged from 72% to 96% [37,38]. Although variation
exists, this alternative regimen seems to have a superior
eradication rate in comparison with CAM-based triple
therapy (82.6% vs. 66% by PP analysis) [39]. In the sequen-
tial regimen, the replacement of CAM by levofloxacin offers
an equal or better eradication rate [39,40].
Nevertheless, the increase of a levofloxacin-resistant
strain has brought about the rapid decline of eradication
rate. The prevalence of the levofloxacin-resistant strains
varies in different regions, ranging between 8% and 31%
[41e43]. Following these findings, the levofloxacin-based
therapy was no longer recommended as first-line regimen.
One study suggested that quinolones may be considered
only in the area where the CAM resistance is >15e20% and
the quinolone-resistance was <10% [38].Second-line therapy
When first-line therapy fails, the Maastricht IV Consensus
Report recommends that the bismuth-containing quadruple
therapy is a choice for second-line therapy [2]. This
regimen consists of a PPI, bismuth, tetracycline, and MET.
Previous studies have shown the eradication rates to be
w80% [44e46]. There are several issues concerning this
regimen, such as the availability of bismuth, the increase in
MET-resistant strains, and the duration of therapy. It has
been suggested that if bismuth is not available, tetracycline
is recommended as the replacement. For duration, a
Korean study has suggested that a 2-week bismuth-
containing quadruple therapy course was more effective
than 1 week treatment (83% vs. 64% by ITT analysis) [17].
As mentioned in the Maastricht IV Consensus Report,
levofloxacin-based triple therapy is the alternative second-
line therapy [2]. This regimen consists of a PPI (standard
dose, b.i.d.), levofloxacin (500 mg, q.d.), and AMX (1 g,
b.i.d.). Gisbert and Morena [47] systematically analyzed
the studies comparing this regimen with bismuth-based
quadruple therapies, and showed a better eradication
rate with borderline significance in levofloxacin-based
regimen groups (81% vs. 70%). The other two randomized
control trials from Taiwan and Hong Kong showed that
levofloxacin-based triple therapy was comparable to
quadruple therapy for eradication efficacy as a second-line
therapy [48,49]. Extending the duration has been suggested
to improve the performance of the regimen. A meta-
analysis from Saad et al. [50] showed that a 10-day
administration of levofloxacin-based therapy was superior
170 T.-S. Wu et al.to a 7-day bismuth-based quadruple therapy. An advantage
of this regimen is fewer adverse effects than with
quadruple regimens (19% vs. 44%) [47]. Most studies eval-
uating the efficacy of this regimen were based on a group
that failed to respond to standard triple therapy. Its per-
formance for patients who failed to eradicate H. pylori by
alternative first-line therapies (such as sequential,
concomitant, or hybrid therapies) remains unclear.Third-line therapy
There is currently still no standard third-line therapy. The
Maastricht IV Consensus Report recommended a selection
of antibiotics for third-line regimens according to the bac-
terial culture with antimicrobial sensitivity tests [2].
Several empirical studies followed this guideline and
the results were impressive [41,45,51,52]. One study was
reported by Cammarota et al. [41]. They evaluated 94 pa-
tients in whom H. pylori infection persisted despite twice-
administered eradication therapies. The antimicrobial
sensitivity test disclosed that the percentage resistance to
MET, CAM, levofloxacin, and tetracycline was 100%, 95%,
31%, and 5%, respectively. Interestingly, no AMX resistance
was found in any of these patients. Finally, H. pylori
eradication was achieved in 90% of these patients treated
by culture-guided therapy.
However, there were some limitations. First, the
H. pylori culture rate was <60% [53]. Second, the culture
rate varied in different institutions and regions, indicating
that nearly half of the patients did not have data for the
antimicrobial sensitivity tests. Furthermore, the in vitro
antimicrobial sensitivity test does not always promise suc-
cessful eradication in vivo. Therefore, several attempts
have been made to substitute for the ineffective culture.
One of them is utilizing molecular methods, such as real-
time polymerase chain reaction, which can detect the
existence of the point mutation on 23S rRNA gene of
H. pylori associated with CAM resistance [54]. The advan-
tages of this method include no need for culture, obtaining
results in a few hours, being commercially available, and
possible detection from feces [54]. The disadvantage is that
each mutation connected to variable antibiotic resistance
needs to be determined, and the cost is possibly high.
Another study from Hsu et al. [51] offered a clue for the
designation of the regimen if the antimicrobial sensitivity is
not available. They designed a 10-day quadruple therapy
comprising rabeprazole (20 mg, b.i.d.), bismuth subcitrate
(300mg,q.i.d. (quater indie, four timesaday)),AMX(500mg,
q.i.d.), and levofloxacin (500 mg, daily). The preferred anti-
biotics are those that have low resistance rates in regional
evaluation (AMX) and which have proven efficacy against H.
pylori but are not used in either first- or second-line regimens
(levofloxacin). This regimen achieved an eradication rate of
84% by both ITT and PP analysis in patients in whom eradica-
tion failed via standard triple therapy and bismuth-based
quadruple therapy [51].
Several new antibiotics have been tried as an alternative
component of H. pylori eradication regimens. One of them is
the antituberculous agent rifabutin. A meta-analysis re-
ported recently demonstrated that the mean H. pylori
eradication rate by rifabutin-containing regimens was 73%(95% CI: 67e79%; ITTanalysis) [55]. The efficacy of rifabutin-
containing therapies as second-line, third-line, and fourth/
fifth-line regimens was 79% (95% CI: 67e92%, 223 cases),
66% (95%CI: 55e77%, 342 cases), and 70% (95%CI: 60e79%, 95
cases) respectively. A study fromGisbert et al. [56],whoused
a 14-day rifabutin-based triple therapy (rifabutin 150 mg,
b.i.d., AMX 1 g, b.i.d., and omeprazole 20 mg, b.i.d.) as a
third-line regimen, showed an acceptable eradication rate
(79% by ITT and PP analysis). Currently, no definite duration
of rifabutin-containing therapies is defined, but 10e12 days
is recommended by most studies.
Unfortunately, myelotoxicity and adverse ocular events
have been reported after rifabutin-based therapy [57].
Besides, extensive use of rifabutin might result in the
development of resistance in Mycobacterium tuberculosis
and Mycobacterium avium. These observations establish
some concern about this regimen in clinical application.
The other medication evaluated in the efficacy of
H. pylori eradication is furazolidone, a nitrofuran antibac-
terial. In a study in which eradication of H. pylori failed
after the second-line 7-day bismuth-based quadruple
therapy, another 7-day bismuth-based quadruple therapy
regimen was administered but MET was replaced by fura-
zolidone, offering a promising eradication rate (90% in both
ITT and PP analysis), indicating that this regimen could be
effective as a third-line therapy [58].
Conclusion
Following the increase in antibiotic-resistant strains, the
successful eradication of H. pylori is a challenge. The
declining eradication rate for the standard triple therapy
makes it not always suitable to be the first-line regimen.
Several new treatment strategies have been introduced
with the intention to overcome antibiotic resistance,
including bismuth-containing quadruple therapy, sequential
therapy, concomitant quadruple therapy, and hybrid ther-
apy. These alternative regimens have been shown to be
reliable as first-line therapies.
Although bismuth-based quadruple therapy is suggested as
the choice of second-line regimen, the unavailability of bis-
muth and antibiotic resistance forces clinicians to seek new
componentsof the regimen.Levofloxacin-based triple therapy
has been proven to offer equal efficacy but has fewer adverse
effects thanbismuth-based regimens.However, it is necessary
topayattentiontothe influenceof the increasing resistance to
levofloxacin. Third-line therapy should be determined in
accordance with the culture and antibiotics susceptibility
data. Several new antibiotics have been tried and proven to
offer acceptable eradication rates, but theassociatedadverse
effects need to be taken into consideration.
ThedifferentCYP2C19genotype influences the intragastric
pH level, as well as the efficacy on eradication [12e14].
Although it is not recommended to check the genotype regu-
larly, it might be important for designing individual regimens
for those cases failing second- or third-line eradication.
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